Phase 1, open label, single dose, 3 way crossover study to evaluate the bioavailability of a solid dose formulation of PF 04965842 relative to a suspension formulation under fasting conditions and the effect of food on the bioavailability of the solid dosage formulation of PF 04965842 in healthy subjects.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
NONE
Enrollment
12
Subjects will receive 4 x 100 mg PF 04965842 tablet under fasted conditions
Subjects will receive 400 mg PF 04965842 oral suspension under fasted conditions
Subjects will receive 4 x 100 mg PF 04965842 tablet under fed conditions
Pfizer Investigational Site
Brussels, Belgium
Area Under the Curve from Time Zero to infinity (AUC inf)
Time frame: 15 days
Maximum Observed Plasma Concentration (Cmax)
Time frame: 15 days
Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast)
Area under the plasma concentration time-curve from zero to the last measured concentration (AUClast)
Time frame: 15 days
Time to Reach Maximum Observed Plasma Concentration (Tmax)
Time frame: 15 days
Plasma Decay Half-Life (t1/2)
Plasma decay half-life is the time measured for the plasma concentration to decrease by one half.
Time frame: 15 days
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.